|
Company:
|
CTI BIOPHARMA CORP (CTIC)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
3/1/2012
|
|
CIK:
|
0000891293
|
|
Address:
|
3101 WESTERN AVENUE
SUITE 600
|
|
City, State, Zip:
|
SEATTLE, Washington 98121
|
|
Telephone:
|
(206) 282-7100
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$2.20
|
Change:
0.03 (1.38%)
|
Trade Time:
Jan 30
|
Market Cap:
$395.54M
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on the acquisition, development and
commercialization of less toxic and more effective ways to treat cancer. Our
goal is to build a profitable company by generating income from products we
develop and commercialize, either alone or with partners. We are currently
concentrating our efforts on treatments that target blood-related cancers where
there is an unmet medical need. We are primarily focused on commercializing
PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed
or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3
clinical trial program of pacritinib for the treatment of myelofibrosis that
will support regulatory submission for approval in the United States, or the
U.S., and Europe.
|
|
|
|